Peptide Dosing — Complete Reference

Complete Peptide Dosing Reference

A comprehensive, structured dosing guide for all FDA-approved and major investigational peptides.

Dosing Conventions

Unit	Definition
µg/kg	Micrograms per kilogram body weight
U	International units (insulin, natriuretic peptides)
SC	Subcutaneous injection
IM	Intramuscular injection
IV	Intravenous infusion or bolus
INH	Pulmonary inhalation
PO	Oral administration

---

GLP-1 Receptor Agonists

Semaglutide (Ozempic) — Type 2 Diabetes

Parameter	Specification
Route	SC injection
Starting dose	0.25 mg once weekly × 4 weeks (not therapeutic)
Titration	0.5 mg weekly after 4 weeks
Therapeutic dose	0.5 mg or 1 mg once weekly
Maximum dose	2 mg once weekly
Dose interval	7 days (±1 day)
Injection sites	Abdomen, thigh, upper arm
Dose adjustment	Based on HbA1c and tolerability
Renal impairment	No adjustment (use caution if eGFR <15)
Hepatic impairment	No adjustment
Pediatric	Not approved <18 years
Missed dose	If >2 days late, skip and resume schedule

Semaglutide (Wegovy) — Obesity

Parameter	Specification
Route	SC injection
Starting dose	0.25 mg once weekly × 4 weeks
Titration	0.5 mg × 4 weeks → 1 mg × 4 weeks → 1.7 mg × 4 weeks → 2.4 mg
Target dose	2.4 mg once weekly
Maximum dose	2.4 mg once weekly
Dose interval	7 days
Weight loss plateau	Reassess at 16 weeks; if <5% weight loss, discontinue

Semaglutide (Rybelsus) — Oral

Parameter	Specification
Route	Oral tablet
Starting dose	3 mg once daily × 30 days
Titration	7 mg once daily after 30 days
Therapeutic dose	7 mg or 14 mg once daily
Maximum dose	14 mg once daily
Administration	Empty stomach, ≤4 oz water, wait 30 min before food/meds
Renal impairment	No adjustment

Tirzepatide (Mounjaro) — Type 2 Diabetes

Parameter	Specification
Route	SC injection
Starting dose	2.5 mg once weekly × 4 weeks
Titration	2.5 mg → 5 mg → 7.5 mg → 10 mg (each × 4 weeks)
Therapeutic dose	5 mg, 10 mg, or 15 mg once weekly
Maximum dose	15 mg once weekly
Dose interval	7 days
Injection sites	Abdomen, thigh, upper arm

Tirzepatide (Zepbound) — Obesity

Parameter	Specification
Route	SC injection
Starting dose	2.5 mg once weekly × 4 weeks
Titration	2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg
Target dose	10 mg or 15 mg once weekly
Maximum dose	15 mg once weekly

Liraglutide (Victoza) — Type 2 Diabetes

Parameter	Specification
Route	SC injection
Starting dose	0.6 mg once daily × 1 week
Titration	1.2 mg → 1.8 mg (weekly increments)
Therapeutic dose	1.2 mg or 1.8 mg once daily
Maximum dose	1.8 mg once daily

Liraglutide (Saxenda) — Obesity

Parameter	Specification
Route	SC injection
Starting dose	0.6 mg once daily × 1 week
Titration	0.6 mg weekly increments to 3.0 mg
Target dose	3.0 mg once daily
Maximum dose	3.0 mg once daily
Weight loss plateau	Reassess at 12 weeks; if <4% weight loss, discontinue

Exenatide (Byetta) — Type 2 Diabetes

Parameter	Specification
Route	SC injection
Starting dose	5 µg twice daily × 30 days
Therapeutic dose	10 µg twice daily
Maximum dose	10 µg twice daily
Administration	Within 60 min before morning and evening meals

Exenatide ER (Bydureon) — Type 2 Diabetes

Parameter	Specification
Route	SC injection
Dose	2 mg once weekly
Administration	Any time of day, with or without food
Suspension	Requires reconstitution

Dulaglutide (Trulicity) — Type 2 Diabetes

Parameter	Specification
Route	SC injection
Starting dose	0.75 mg once weekly
Titration	0.75 mg → 1.5 mg → 3.0 mg → 4.5 mg
Therapeutic dose	0.75 mg, 1.5 mg, 3.0 mg, or 4.5 mg
Maximum dose	4.5 mg once weekly

Lixisenatide (Adlyxin) — Type 2 Diabetes

Parameter	Specification
Route	SC injection
Starting dose	10 µg once daily × 14 days
Therapeutic dose	20 µg once daily
Administration	Within 1 hour before breakfast

Oral Semaglutide Agents (Investigational)

Agent	Starting Dose	Target Dose	Frequency	Status
Orforglipron	12 mg	36 mg	Daily	Phase III
Danuglipron	120 mg	120 mg	BID	Phase II

---

Amylin Analogues

Pramlintide (Symlin) — Type 1/2 Diabetes

Parameter	Specification
Route	SC injection
Starting dose (T1D)	15 µg before meals
Starting dose (T2D)	60 µg before meals
Titration (T1D)	15 µg increments to 60 µg
Titration (T2D)	60 µg fixed
Maximum dose	60 µg before meals
Administration	Before major meals (≥300 kcal)
Insulin adjustment	↓Insulin bolus 50% when initiating

---

Insulin Analogues

Rapid-Acting Insulins

Insulin	Onset	Peak	Duration	Starting Dose
Lispro (Humalog)	10–15 min	30–90 min	3–5 h	4–6 U before meals
Aspart (NovoRapid)	10–15 min	30–90 min	3–5 h	4–6 U before meals
Glulisine (Apidra)	10–15 min	30–90 min	3–5 h	4–6 U before meals
Faster aspart (Fiasp)	5–10 min	15–30 min	3–5 h	4–6 U before meals
Technosphere (Afrezza)	5–10 min	12–15 min	1.5–3 h	4 U before meals

Long-Acting Insulins

Insulin	Onset	Peak	Duration	Starting Dose
Glargine U-100 (Lantus)	1–2 h	Peakless	24 h	10 U or 0.2 U/kg
Glargine U-300 (Toujeo)	1–6 h	Peakless	30+ h	1.5× previous dose
Detemir (Levemir)	1–2 h	6–8 h	18–24 h	10 U or 0.1–0.2 U/kg
Degludec (Tresiba)	1–2 h	Peakless	42+ h	10 U or 0.1 U/kg
Icodec (Awiqli)	1–6 h	Peakless	7+ days	70 U or 1 U/kg/week

---

Growth Hormone Secretagogues

Tesamorelin (Egrifta) — HIV Lipodystrophy

Parameter	Specification
Route	SC injection
Dose	2 mg once daily
Timing	Within 2 hours after evening meal
Duration	26 weeks, then reassess
Reconstitution	Use provided diluent

Sermorelin (Investigational) — GH Deficiency

Parameter	Specification
Route	SC injection
Dose	0.3–0.5 µg/kg/day
Timing	Bedtime (mimics physiological pulse)
Duration	6–12 months

CJC-1295 DAC (Investigational)

Parameter	Specification
Route	SC injection
Dose	30–60 µg/kg or 2 mg weekly
Timing	Bedtime (mimics nocturnal GHRH)
Duration	1–6 months

Ipamorelin (Investigational)

Parameter	Specification
Route	SC injection
Dose	200–300 µg 2–3× daily
Timing	Fasting state, before meals
Duration	1–6 months

---

Melanocortin Analogues

Afamelanotide (Scenesse) — EPP

Parameter	Specification
Route	SC implant
Dose	16 mg
Frequency	Every 2 months
Administration	SC implant (abdomen or thigh)
Sun exposure	Avoid for 48 hours after implant

Bremelanotide (Vyleesi) — FSD

Parameter	Specification
Route	SC injection
Dose	1.75 mg
Timing	≥45 min before anticipated sexual activity
Maximum	1 dose per 24 hours
Nausea management	Take with antiemetic if needed

---

Somatostatin Analogues

Octreotide (Sandostatin) — Acromegaly/NET

Parameter	Specification
Route	SC or IM
Starting dose	100–500 µg SC TID or 20–30 mg IM monthly
Titration	100 µg increments every 2 weeks
Maximum dose	1500 µg/day SC or 40 mg/month IM
Long-acting (LAR)	20–30 mg IM monthly

Lanreotide (Somatuline) — Acromegaly/NET

Parameter	Specification
Route	SC injection
Dose	60–120 mg every 28 days
Administration	Deep SC injection (buttock)

Pasireotide (Signifor) — Cushing’s/NET

Parameter	Specification
Route	SC or IM
SC dose	600–900 µg BID
IM dose (LAR)	10–40 mg monthly
Titration	Based on UFC levels

---

Oxytocin/Vasopressin Analogues

Oxytocin — Labor/Postpartum

Parameter	Specification
Route	IV infusion
Induction	1–2 mU/min, titrate q30–60 min
Maximum	20–40 mU/min
Postpartum hemorrhage	10–40 U IV bolus or infusion

Desmopressin (DDAVP) — Diabetes Insipidus

Parameter	Specification
Route	SC/IV/Nasal/Oral
SC/IV dose	1–4 µg/day in 2–3 divided doses
Nasal spray	10–40 µg/day in 2–3 divided doses
Oral	60–360 µg/day in divided doses

Carbetocin — Postpartum Hemorrhage

Parameter	Specification
Route	IV or IM
Dose	100 µg single dose
Timing	After delivery of placenta

---

Natriuretic Peptides

Nesiritide (Natrecor) — Acute Heart Failure

Parameter	Specification
Route	IV infusion
Loading dose	2 µg/kg IV bolus
Maintenance	0.01 µg/kg/min × 24 hours
Maximum	Not to exceed 0.03 µg/kg/min

---

Antiplatelet Peptides

Eptifibatide (Integrilin) — ACS

Parameter	Specification
Route	IV infusion
ACS dose	180 µg/kg bolus → 2 µg/kg/min × 18–24 h
PCI dose	180 µg/kg bolus → 2 µg/kg/min × 18–24 h
Renal adjustment (CrCl <50)	1 µg/kg/min

Tirofiban (Aggrastat) — ACS

Parameter	Specification
Route	IV infusion
Dose	25 µg/kg over 3 min → 0.15 µg/kg/min × 18–48 h
Renal adjustment	50% dose reduction if CrCl <60

---

Thymic Peptides

Thymosin Alpha-1 — Immunomodulation

Parameter	Specification
Route	SC injection
Dose	1.6 mg
Frequency	Daily or every other day
Duration	4–12 weeks (varies by indication)

---

Special Populations

Renal Impairment

Peptide	Mild (eGFR 60–89)	Moderate (eGFR 30–59)	Severe (eGFR <30)
Semaglutide	No adjustment	No adjustment	Use caution
Tirzepatide	No adjustment	No adjustment	No data
Insulin	No adjustment	↓Dose 25%	↓Dose 50%
Octreotide	No adjustment	No adjustment	No adjustment
Eptifibatide	No adjustment	↓Dose	Contraindicated
Tirofiban	No adjustment	↓Dose 50%	↓Dose 50%

Hepatic Impairment

Peptide	Mild (Child-Pugh A)	Moderate (B)	Severe (C)
Semaglutide	No adjustment	No adjustment	No data
Insulin	No adjustment	↓Dose	↓Dose
Octreotide	No adjustment	No adjustment	Use caution

Pediatric Dosing

Peptide	Age	Dose
Insulin lispro	≥3 years	Weight-based
Insulin glargine	≥6 years	0.5 U/kg/day
Insulin degludec	≥1 year	0.5 U/kg/day
Somatropin	≥1 year	0.025–0.05 mg/kg/day
Octreotide	≥6 years	Adult doses
Pramlintide	≥18 years	Adult doses

Geriatric Dosing

Consideration	Recommendation
Start low	Use lowest effective dose
Titrate slowly	Slower titration intervals
Renal monitoring	More frequent monitoring
Hypoglycemia risk	Educate, use CGM if possible

---

References

• Peptide Clinical Dosing
• Peptide Storage Conditions
• Peptide Reconstitution Guide
• Peptide Safety Data
• Peptide Drug Interactions Database